Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8143212 | ALLERGAN | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(9 months from now) | |
US7119061 | ALLERGAN | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(9 months from now) | |
US7115564 | ALLERGAN | Stable pharmaceutical compositions of dalbavancin and methods of administration |
Nov, 2023
(9 months from now) | |
US6900175 | ALLERGAN | Methods of administering dalbavancin for treatment of bacterial infections |
Dec, 2023
(10 months from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 23, 2019 |
New Patient Population (NPP) | Jul 22, 2024 |
Generating Antibiotic Incentives Now (GAIN) | May 23, 2024 |
NCE-1 date: May, 2023
Market Authorisation Date: 23 May, 2014
Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.
Dosage: POWDER;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic